MASI vs ICUI

For growth investors, ICU Medical, Inc.

(ICUI) is the stronger pick with -6. 3% revenue growth year-over-year, versus -27. 1% for Masimo Corporation (MASI). ICU Medical, Inc. (ICUI) offers the better valuation at 3986. 3x trailing P/E (14. 8x forward), making it the more compelling value choice. Analysts rate Masimo Corporation (MASI) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, ICU Medical, Inc.

is actually cheaper at 14. 8x.

Over the past 5 years, Masimo Corporation (MASI) delivered a total return of -19.

4%, compared to -43. 3% for ICU Medical, Inc. (ICUI). Over 10 years, the gap is even starker: MASI returned +287. 3% versus ICUI's +17. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Masimo Corporation (MASI) is the lower-risk stock at 0.

63β versus ICU Medical, Inc. 's 1. 23β — meaning ICUI is approximately 96% more volatile than MASI relative to the S&P 500. On balance sheet safety, ICU Medical, Inc. (ICUI) carries a lower debt/equity ratio of 60% versus 78% for Masimo Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ICU Medical, Inc.

(ICUI) is pulling ahead at -6. 3% versus -27. 1% for Masimo Corporation (MASI). On earnings-per-share growth, the picture is similar: ICU Medical, Inc. grew EPS 100. 6% year-over-year, compared to 51. 0% for Masimo Corporation. Over a 3-year CAGR, ICUI leads at -0. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ICU Medical, Inc.

(ICUI) is the more profitable company, earning 0. 3% net margin versus -9. 9% for Masimo Corporation — meaning it keeps 0. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MASI leads at 20. 5% versus 1. 9% for ICUI. At the gross margin level — before operating expenses — MASI leads at 61. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ICU Medical, Inc.

(ICUI) trades at 14. 8x forward P/E versus 32. 5x for Masimo Corporation — 17. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ICUI: 36. 7% to $163. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Masimo Corporation (MASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

63), +287. 3% 10Y return). Both have compounded well over 10 years (MASI: +287. 3%, ICUI: +17. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.